Doxorubicin-Eluting Beads

Phase 3Small molecule

NNational Cancer Institute (NCI)

Doxorubicin-Eluting Beads is one of 66 small molecule programs targeting Liver Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Liver CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Hepatocellular CancerActive, not recruiting

Liver CancerPhase 3

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Hepatocellular CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

797 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Doxorubicin-Eluting Beads

NNational Cancer Institute (NCI)

Phase 3

5 2

Cysteine Hydrochloride

Novartis

Preclinical

1 3

Ibrance

Pfizer

Preclinical

1 4

Viread

Gilead

Preclinical

1 5

Hepsera

Coreg

2 7

Apatinib

LLaNova Medicines Zhejiang Co., Ltd.

Preclinical

16 8

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Statin

1 10

Anlotinib

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Hepatocellular Cancer

NCT03937830

Clinical

Trials by Indication[1]

Liver Cancer3 trials

Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Unknown status·UUniversity College, London·Phase 3·NCT01324076·412 enrolled

Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer

Terminated·SSwiss Cancer Institute·Phase 1/2·NCT01009801·27 enrolled

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01004978·235 enrolled

Treatment1 trial

Role of DEB-TACE Versus c-TACE in Treatment of HCC

Unknown status·SSohag University·Phase 1·NCT05093920·30 enrolled

Hepatocellular Cancer1 trial

A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT03937830·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Doxorubicin-Eluting Beads. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxorubicin-Eluting Beads compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxorubicin-Eluting Beads. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Cancer Institute (NCI)

Doxorubicin-Eluting Beads

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Liver Cancer3 trials

Treatment1 trial

Hepatocellular Cancer1 trial

References

Drug Info

Quick Facts

Related News